title: Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B.
abstract: Prostate cancer is the most common malignant tumor in men and is normally associated with increased serum levels of prostate-specific antigen (PSA). Therefore, PSA is one potential target for a prostate cancer vaccine. In this study we analyzed the functionality of new bacterial PSA vaccines, expressed and secreted via the hemolysin (HlyA) secretion system of Escherichia coli, the prototype of Type I secretion systems (T1SS) using an attenuated Salmonella enterica serovar Typhimurium aroA strain as carrier. The data demonstrate that a bacterial live vaccine encompassing T1SS in combination with cholera toxin subunit B can be successfully used for delivery of PSA to induce cytotoxic CD8+ T-cell responses resulting in an efficient prevention of tumor growth in mice.
authors: Institut für Medizinische Strahlenkunde und Zellforschung, University of Wuerzburg, Wuerzburg, Germany.
authors: J
authors: J
authors: Fensterle
authors: B
authors: B
authors: Bergmann
authors: C L R P
authors: CL
authors: Yone
authors: C
authors: C
authors: Hotz
authors: S R
authors: SR
authors: Meyer
authors: S
authors: S
authors: Spreng
authors: W
authors: W
authors: Goebel
authors: U R
authors: UR
authors: Rapp
authors: I
authors: I
authors: Gentschev
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D002772:Cholera Toxin / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D029968:Escherichia coli Proteins / Q000235:genetics / Q000378:metabolism; D005260:Female; D006460:Hemolysin Proteins / Q000235:genetics / Q000378:metabolism; D006801:Humans; D016233:Immunotherapy, Active; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D017430:Prostate-Specific Antigen / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000276:immunology / Q000517:prevention & control*; D022562:Salmonella Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D012486:Salmonella typhimurium / Q000235:genetics* / Q000276:immunology; D014436:Typhoid-Paratyphoid Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; D029968:Escherichia coli Proteins; D006460:Hemolysin Proteins; C036507:Hlya protein, E coli; D022562:Salmonella Vaccines; D014436:Typhoid-Paratyphoid Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; C087350:aroA Salmonella vaccine; D002772:Cholera Toxin; D017430:Prostate-Specific Antigen